For the quarter ending 2026-03-31, FHTX had $6,787K increase in cash & cash equivalents over the period. -$25,266K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -19,875 | -21,664 | -52,619 | - |
| Stock-based compensation expense | 2,383 | 2,241 | 2,733 | 5,425 |
| Depreciation and amortization expense | 238 | 802 | 852 | 1,678 |
| Loss on disposal of property and equipment | - | -31 | - | - |
| Gain on lease modification | - | 1,632 | - | - |
| Impairment of long-lived assets | - | 5,914 | 0 | - |
| Noncash lease expense | 561 | 543 | 696 | 2,967 |
| Accretion of discount on marketable securities | 388 | 306 | 356 | 1,264 |
| Prepaid expenses and other current assets | 91 | 501 | -1,339 | -1,989 |
| Accounts payable | -990 | 1,054 | -110 | -463 |
| Accrued expenses and other liabilities | -4,458 | 1,435 | 1,157 | -388 |
| Operating lease liabilities | 621 | -941 | -1,169 | -4,633 |
| Deferred revenue | -3,267 | -9,247 | -8,153 | -13,509 |
| Net cash used in operating activities | -25,266 | -22,271 | -18,860 | -44,968 |
| Purchases of property and equipment | 0 | 0 | 0 | 50 |
| Purchases of marketable securities | 66,938 | 33,981 | 4,002 | 93,264 |
| Proceeds from maturities of marketable securities | 49,219 | 47,213 | 39,575 | 156,549 |
| Net cash provided by (used in) investing activities | -17,719 | 13,232 | 35,573 | 63,235 |
| Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-Prefunded Warrants | - | 0 | - | - |
| Proceeds from offerings of common stock, pre-funded warrants, and series warrants net of underwriting discounts and commissions | 49,999 | - | 0 | 0 |
| Payments of public offering costs | 316 | 0 | 0 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan | 89 | 41 | 49 | 393 |
| Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-At Market Offering | - | 540 | - | - |
| Net cash provided by financing activities | 49,772 | 581 | 49 | 393 |
| Net increase in cash, cash equivalents and restricted cash | 6,787 | -8,458 | 16,762 | 18,660 |
| Cash, cash equivalents and restricted cash at beginning of period | 84,126 | 92,584 | 57,162 | - |
| Cash, cash equivalents and restricted cash at end of period | 90,913 | 84,126 | 92,584 | - |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)